ReviewCurrent questions regarding the use of statins in patients with coronary heart disease
Section snippets
Benefits of aggressive lipid lowering treatment
The first randomized clinical trials with statins during the 90's [5], [6], [7], [8], [9], reported and confirmed the clinical benefits from statin treatment in primary and secondary prevention of CHD. Then, the U.S. National Cholesterol Education Program (NCEP) Adult Treatment Panel III guidelines in 2001 were released [10], and set the target LDL cholesterol level in CHD patients < 100 mg/dL. During the following 5 years statin trials tested mainly the outcome of early intensive treatment in
How early do the clinical benefits appear after the initiation of intensive lipid lowering therapy?
Early statin trials [5], [6], [7], [8], [9] of primary and secondary prevention of stable CHD showed that the clinical benefit is evident 1–2 years after the initiation of treatment. This delay, however, did not appear in the most recent trials using statins in ACS [11], [13]. Indeed, analysis from the PROVE IT-TIMI 22 trial [19], showed that the clinical benefit from the intensive lipid lowering therapy in patients with ACS, started to emerge as early as 15 days after the initiation of
How safe are the statins?
Skepticism over statin safety was raised after the worldwide withdrawal of cerivastatin in 2001 because of its association with fatal rabdomyolysis. As a result the safety profile of rosuvastatin, the most recently launched statin, had been the subject of increased scrutiny before its approval by the US Food and Drug Administration (FDA).
Accumulating data show that statins are safe drugs [36], [37], [38], [39], [40], [41]. The main concerns related to statin treatment are:
- a)
liver toxicity. This
How safe are the very low LDL cholesterol levels achieved by statin treatment?
Such a question is reasonable, since cholesterol is an essential component of cellular membranes and is also necessary for steroid hormones and vitamin D synthesis. However, the answer is not straightforward since only few data exist regarding the safety of very low levels of LDL cholesterol, achieved by intensive statin therapy.
Hunter/gatherer populations (e.g. Pygmies) that continue to live primitively and in whom atherosclerosis is rare or non existent, have cholesterol levels in the range
Is targeting only LDL cholesterol enough?
Several studies have shown that statins reduce CRP levels [57], [58] and that more robust LDL cholesterol reductions are correlated with lower CRP levels [59]. The potential benefit of achieving not only low LDL cholesterol levels, but also low CRP levels has also been investigated. In the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial, the least reduction in atherosclerosis was noted in those who achieved the greatest reduction in both LDL cholesterol and CRP
Can intensive lipid lowering therapy cause a regression of coronary atherosclerosis?
The question of whether statins can affect the progression of coronary atherosclerosis has been examined since the early 90s [62], [63]. In the first statin studies, where quantitative coronary angiography was used to assess the progression rates, no regression was detected. The absence of angiographic regression, despite the clinical benefits, generated the “stabilization” hypothesis of the plaque and this stabilizing effect was attributed to the pleiotropic properties of statins [63].
Conclusions
There is substantial evidence regarding the clinical benefit of statins both in primary and secondary prevention of CHD. Statins are drugs with a good safety profile. Recent findings suggest that the benefits of statins in CHD patients can be maximised when: a) statins are used in high doses, b) statins are started early in patients with ACS and c) a significant reduction of CRP (< 2 mg/L) besides LDL cholesterol reduction is achieved. This is despite the fact that a substantial proportion of
References (65)
- et al.
Contemporary management of dyslipidemia in high-risk patients: targets still not met
Am J Med
(2006) - et al.
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes
J Am Coll Cardiol
(2005) - et al.
The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes
J Am Coll Cardiol
(2005) - et al.
Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells
J Thromb Haemost
(2004) - et al.
Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion
Int J Cardiol
(2002) - et al.
Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells
Atherosclerosis
(2000) - et al.
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy
J Am Coll Cardiol
(2003) Treating dyslipidemia with statins: the risk–benefit profile
Am J Cardiol
(2003)- et al.
Pravastatin in patients with nonalcoholic steatohepatitis. Results of a pilot study
Atherosclerosis
(2004) - et al.
Clinical perspectives of statin-induced rhabdomyolysis
Am J Med
(2006)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial
Lancet
Do statins cause cancer? A meta-analysis of large randomized clinical trials
Am J Med
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)
Lancet
Effects of statins on renal function
Am J Cardiol
Optimal low-density lipoprotein is 50 to 70 mg/dl. Lower is better and physiologically normal
J Am Coll Cardiol
Coronary artery disease prognosis and C-reactive protein levels improve in proportion to percent lowering to low density lipoprotein
Am J Cardiol
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol < 70 mg/dl and C-reactive protein < 2 mg/l
J Am Coll Cardiol
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins
Lancet
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals: a randomized placebo controlled trial
Lancet
High prevalence and suboptimal treatment of risk factors in Greek coronary patients
Acta Cardiol
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
N Engl J Med
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sinvastatin Survival Study (4S)
Lancet
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
N Engl J Med
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level
N Engl J Med
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
JAMA
Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JAMA
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial
JAMA
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial
JAMA
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
N Engl J Med
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
N Engl J Med
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
JAMA
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
Circulation
Cited by (18)
Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors
2017, European Journal of Medicinal ChemistryCitation Excerpt :The large phase III clinical outcome trial of Anacetrapib is also ongoing to determine the safety and efficacy in patients with atherosclerotic cardiovascular diseases [14]. Recent research findings showed that Anacetrapib reduced progression of atherosclerosis by systematically reducing non-HDL-cholesterol, improved lesion stability and added to the beneficial effects of atorvastatin [15]. Nevertheless, almost all the reported CETP inhibitors exhibited highly lipophilic and poorly aqueous soluble characteristics [11], which might be an unfavorable factor for their discovery and clinical development [16].
PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
2016, Hellenic Journal of CardiologyCitation Excerpt :Despite the large benefit, a significant number (∼15-20%) of CAD patients on statin treatment still develop CV events within a five-year period. Τhis may be due to failure to attain LDL-C goals, to co-existence of other risk factors, such as diabetes mellitus, Lp(a), and atherogenic dyslipidaemia, that are not treated sufficiently with existing drugs, or to the presence of other, as yet unknown, CAD risk factors .36 Failure to achieve LDL-C levels was shown in the EUROASPIRE (European Action on Secondary and Primary Prevention by Intervention to Reduce Events) IV trial,37 which recorded risk factors from 24 European countries in individuals with established CAD.
Drugs for lipid disorders, antiplatelet drugs and fibrinolytics
2014, Medicine (United Kingdom)Citation Excerpt :There is usually a modest rise in HDL cholesterol of about 5%. The LDL-cholesterol reduction can be as much as 50% and is dependent on the dose and the efficacy of the drug used.2,3 Non-lipid effects of statins, including the stabilization of atherosclerotic plaques and a decrease in inflammatory cell infiltrate, are becoming increasingly recognized.4,5
Drugs for lipid disorders, antiplatelet drugs and fibrinolytics
2010, Medicine (United Kingdom)Perspectives of the non-statin hypolipidemic agents
2010, Pharmacology and TherapeuticsShould statins be given routinely in all coronary patients?
2009, International Journal of Cardiology